EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Optimal dose of rituximab in ABO‐incompatible kidney transplantation in patients with low anti‐A/B antibody titers: A single‐center retrospective cohort study

Manabu Okada iD, Shunji Narumi, Yuki Hasegawa, Kenta Futamura, Takahisa Hiramitsu, Toshihiro Ichimori, Norihiko Goto, Takaaki Kobayashi iD, Kazuharu Uchida, Asami Takeda, Yoshihiko Watarai

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14915 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Manabu Okada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical outcomes of ABO‐incompatible (ABOi) kidney transplantation have improved with the introduction of desensitization therapy with rituximab. However, rituximab prevents not only antibody‐mediated rejection (AMR) but also increases the risk of adverse events, such as infection. For ABOi kidney transplantation in patients with low anti‐A/B antibody titers, we previously used a rituximab‐free desensitization protocol and then initiated a single dose of 100 mg rituximab in 2016. We retrospectively compared the outcomes of ABOi kidney transplantation in patients with low anti‐A/B antibody titers before and after the introduction of rituximab.

Methods

ABOi kidney transplantations ( n = 142) in patients with low anti‐A/B antibody titers between 2007 and 2021 were included. Patients were divided into two groups (with and without rituximab) for desensitization. The primary outcomes were the incidence of acute AMR and infection.

Results

Sixty‐six patients were desensitized without rituximab (rituximab‐free group), and 76 were pretreated with 100 mg rituximab (rituximab group) before transplantation. The incidence of acute AMR was significantly lower in the rituximab group than in the rituximab‐free group (.0% [0/76] vs. 7.6% [5/66], respectively; p = .047). Post‐transplantation anti‐A/B antibody titers were also lower in the rituximab group than in the rituximab‐free group. There was no significant difference in the incidence of adverse events, including infections, between the two groups.

Conclusion

In ABOi kidney transplantation patients with low anti‐A/B antibody titers, the desensitization protocol with a single dose of 100 mg rituximab was effective in preventing acute AMR without increasing the risk of other adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationHumansRituximabRetrospective StudiesTreatment OutcomeAntibodiesBlood Group IncompatibilityABO Blood-Group SystemGraft RejectionGraft SurvivalLiving Donors

Stichwörter der Autor:innen

ABO-incompatibilitydesensitizationkidney transplantationrituximab

Substanzen

RituximabAntibodiesABO Blood-Group System

Autor:innen und Institutionen

  • Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
  • Department of Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
  • Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Department of Renal Transplant Surgery, Masuko Memorial Hospital, Nagoya, Japan.
  • Department of Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.

ORCID-Profile: Manabu Okada, Takaaki Kobayashi

Zitieren

APA

Okada, M., Narumi, S., Hasegawa, Y., Futamura, K., Hiramitsu, T., Ichimori, T., Goto, N., Kobayashi, T., Uchida, K., Takeda, A., & Watarai, Y. (2023). Optimal dose of rituximab in ABO‐incompatible kidney transplantation in patients with low anti‐A/B antibody titers: A single‐center retrospective cohort study. Clinical Transplantation. https://doi.org/10.1111/ctr.14915

Vancouver

Okada M, Narumi S, Hasegawa Y, Futamura K, Hiramitsu T, Ichimori T, et al. Optimal dose of rituximab in ABO‐incompatible kidney transplantation in patients with low anti‐A/B antibody titers: A single‐center retrospective cohort study. Clinical Transplantation. 2023. doi:10.1111/ctr.14915

BibTeX
@article{Okada2023,
  author = {Okada, Manabu and Narumi, Shunji and Hasegawa, Yuki and Futamura, Kenta and Hiramitsu, Takahisa and Ichimori, Toshihiro and Goto, Norihiko and Kobayashi, Takaaki and Uchida, Kazuharu and Takeda, Asami and Watarai, Yoshihiko},
  title = {Optimal dose of rituximab in ABO‐incompatible kidney transplantation in patients with low anti‐A/B antibody titers: A single‐center retrospective cohort study},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14915}
}
Kostenlos starten →